Combining antiplatelet and anticoagulant therapy in cardiovascular disease

Area of Science:

• Cardiology
• Pharmacology
• Internal Medicine

Background:

• Atrial fibrillation affects over 3 million Americans, with up to 10% experiencing acute coronary syndrome or percutaneous coronary intervention.
• Concurrent antithrombotic therapy is common but increases major bleeding risk.
• Balancing thrombotic risk reduction with bleeding prevention is a critical clinical challenge.

Purpose of the Study:

• To review recent evidence on antithrombotic strategies in patients with atrial fibrillation and concurrent thrombotic conditions.
• To evaluate combinations of anticoagulation and antiplatelet agents for minimizing bleeding risk.
• To provide guidance on optimizing antithrombotic therapy to reduce adverse medication events.

Main Methods:

• Review of randomized clinical trials over the past 5 years.
• Analysis of different combinations of anticoagulation and antiplatelet agents.
• Evaluation of the role of proton pump inhibitors in reducing gastrointestinal bleeding.

Main Results:

• Shorter treatment durations with fewer antithrombotic agents are generally effective.
• Direct oral anticoagulants combined with clopidogrel show promise.
• Very low-dose rivaroxaban plus aspirin benefits atherosclerotic diseases.
• Proton pump inhibitors may reduce upper gastrointestinal bleeding risk.

Conclusions:

• Optimizing antithrombotic regimens, including shorter courses and specific drug combinations, can reduce bleeding events.
• Direct oral anticoagulants and clopidogrel represent a favorable option.
• Proton pump inhibitor use should be considered for high-risk patients.
• Evidence-based application of these strategies can prevent adverse medication events.